Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0DV8Z
|
|||
| Drug Name |
Elezanumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40] | Phase 2 | [1] | |
| Spinal cord injury [ICD-11: ND51.2] | Phase 2 | [2] | ||
| Company |
AbbVie
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Repulsive guidance molecule A (RGMA) | Target Info | Inhibitor | [3] |
| KEGG Pathway | TGF-beta signaling pathway | |||
| Axon guidance | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03737812) A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04295538) Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (ELASCI). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.